Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · GYRE THERAPEUTICS, INC. (GYRE)

Gyre Therapeutics updates corporate presentation; ETUARY FY26 revenue guide $100.5M-$111M

Neutral Impact 2 of 5 other Written later

Gyre Therapeutics made an updated corporate presentation available on its website on September 1, 2026, and furnished it as Exhibit 99.1 to a Form 8-K under Item 7.01 (Regulation FD Disclosure). The deck restates the company's FY26 total revenue guidance for ETUARY of $100.5M-$111M and a potential F351 launch in early 2027, and the filing itself reports no new financial results.

Key points

  • Presentation made available on the company's website on September 1, 2026; dated September 2026 and furnished as Exhibit 99.1.
  • ETUARY FY26 total revenue guidance shown as $100.5M-$111M.
  • F351 (hydronidone) NDA accepted by China's NMPA in May 2026, with potential launch after the NMPA decision in early 2027.

The filing

CompanyGYRE THERAPEUTICS, INC. (GYRE)
Form8-K, current report
Filed with the SECSep 1, 2026, 9:00 AM ET
Accession number0001140361-26-035189

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 01, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.